- Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
- First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
- Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
- Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.35 |
---|---|
High | 12.72 |
Low | 11.75 |
Bid | 11.46 |
Offer | 13.00 |
Previous close | 12.32 |
Average volume | 344.16k |
---|---|
Shares outstanding | 43.12m |
Free float | 38.49m |
P/E (TTM) | -- |
Market cap | 540.23m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼